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Genomic and precision medicine research has afforded notable advances in human cancer
treatment, yet applicability to other species remains uncertain. Through whole-exome and
transcriptome analyses of 191 spontaneous canine mammary tumors (CMTs) that exhibit the
archetypal features of human breast cancers, we found a striking resemblance of genomic
characteristics including frequent PIK3CA mutations (43.1%), aberrations of the PI3K-Akt
pathway (61.7%), and key genes involved in cancer initiation and progression. We also
identified three gene expression-based CMT subtypes, one of which segregated with basal-
like human breast cancer subtypes with activated epithelial-to-mesenchymal transition, low
claudin expression, and unfavorable disease prognosis. A relative lack of ERBB2 amplification
and Her2-enrichment subtype in CMT denoted species-specific molecular mechanisms.
Taken together, our results elucidate cross-species oncogenic signatures for a better
understanding of universal and context-dependent mechanisms in breast cancer develop-
ment and provide a basis for precision diagnostics and therapeutics for domestic dogs.
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Cancer arises in dogs of all ages, just as in humans. Unlikecommonly used animal models with artificial geneticmodifications, canine tumors occur spontaneously with an
intact immune system in ordinary living environments1. More-
over, in addition to similarities in anatomy and physiology
between dogs and humans, canine tumors also exhibit the prin-
cipal pathologic features of human cancers, including a long-term
oncogenic setting, intratumoral heterogeneity, acquired resistance
to treatment, and distant metastases2. Hence, canine tumors are
invaluable representatives for human cancer research3,4. Among
canine tumors, canine mammary tumors (CMTs) are the most
common in female dogs5 and have been studied for a long time6.
CMTs share molecular and clinical features with human breast
cancers7, providing a basis for the adoption of classification sys-
tems including genetic, morphological, and prognostic elements8.
Nowadays, calls for a deeper understanding of the molecular
characteristics of CMTs are growing in order to uncover cross-
species hallmarks of cancer and to provide better opportunities
for treating cancers in dogs.
Despite their apparent similarities, CMTs and human breast
cancers show molecular and histological discrepancies that have
perplexed veterinary and cancer researchers. For example, unlike
in human breast cancers, the clinical benefits of Her2 amplifica-
tions and their association with Her2 overexpression are not
straightforward in CMTs9,10, putting into question the incidence
and potential clinical utility of ERBB2 amplification in CMTs.
Moreover, the histological features of CMTs differ from those of
human breast cancer. For example, benign tumors are more
prevalent in CMTs (i.e., half of the observed cases)11. And tumors
with mesenchymal origins (e.g., fibrosarcomas and carcino-
sarcomas) and proliferation of myoepithelial cells (e.g., complex
adenomas/carcinomas) are often found in CMTs, all of which are
extremely rare in human breast cancers12. These observations
may imply the presence of distinctive mechanisms underlying
carcinogenesis and cancer progression in and the need for more-
specified therapeutic strategies for CMTs.
Several studies have attempted to advance understanding of the
genetic landscape underlying CMTs. Beck et al.13 documented
CMT-specific gene fusions and deletions using low-depth genome
sequencing of five cases. Gene expression profiling revealed
genetic markers of disease progression and locoregional
metastasis14,15. More recently, Liu et al.16 employed whole-exome
sequencing (WES) and RNA sequencing (RNA-seq) of 12 CMT
cases to identify histology-specific genetic alterations in CMTs:
the authors proposed somatic alterations and epigenetic altera-
tions as markers for simple and complex carcinomas, respectively.
However, the mutational landscape of CMTs remains somewhat
unclear owing to the small cohort sizes and lack of integrative
analysis in these studies. We presumed that multi-omics profiling
of CMTs in a large cohort, as in research into human cancers,
would lead to better understanding of the underlying molecular
pathogenesis of CMTs and inter-species relationships with
human cancer.
Here, we report our analysis of WES and transcriptome-
sequencing (RNA-seq) data for 191 CMT cases, as the first
cohort-level multi-omics study in canine cancers. Our study
covers most of the latest genomic analyses applied in human
cancer research, including the landscape of somatic mutations
and involved pathways, mutational features (mutation burden
and signatures), clonal selection, subtype specificity, gene
expression, molecular subtyping, immune microenvironment,
and survival analysis. We show a notable similarity between CMT
and human breast cancers in terms of recurrent aberration in
oncogenic pathways, which suggests molecular convergence of
carcinogenesis, and highlight a number of novel CMT-specific
mutations and their effects on tumor characteristics. Inclusion of
a substantial number of benign tumors, which are usually not
available in human, was relied upon to identify oncogenic char-
acteristics in early cancer development. Finally, our study outlines
molecular subtypes of prognostic relevance and suggests a need
for the discovery of novel biomarkers of CMTs with which to
facilitate early diagnosis for curative surgery and to develop tar-
geted therapies.
Results
Research cohort. All CMT specimens were obtained from 191
female dogs after curative surgery. Clinicopathological informa-
tion for the cohort is summarized in Supplementary Data 1. The
cohort comprised three histology types in 43 benign tumors
(17 simple and 15 complex adenomas and 11 benign mixed
tumors) and >5 histology types in 148 malignant tumors
(78 simple and 44 complex carcinomas, 17 carcinomas in benign
mixed tumors, and 9 others, including 4 osteosarcomas and 3
carcinosarcomas). The most frequent histologic type in the cohort
was simple carcinoma, 63% (49/78) of which were of tubulopa-
pillary type, resembling the natural incidence of malignant CMT8.
The average age at diagnosis was 11.8 years. In total, WES data
for 183 cases (all with matched blood sequencing data) and RNA-
seq data for 157 cases (64 cases with matched normal tissue
sequencing data) were obtained and further analyzed to ascertain
the genomic and transcriptomic landscape of CMT. Sequencing
information for WES and RNA-seq are available in Supplemen-
tary Data 2 and 3, respectively.
Somatic mutation profiles of the CMT genome. By comparing
the tumor and matched normal sequencing data, we identified
two types of somatic alterations: single-nucleotide substitution/
variations (SNVs) and short insertions/deletions (indels). A total
of 10,855 exonic mutations (8569 SNVs and 2286 indels, Sup-
plementary Data 4) were identified for 183 cases with WES by a
customized variant calling pipeline that includes strict filtration
and canine-specific annotation (see Methods). The mutation
landscape for nine recurrently mutated genes in CMT (eight
genes harboring non-silent mutations for >5% of cases and
AKT1) is depicted in Fig. 1a.
Among the somatic mutations, PIK3CA mutations were the
most frequent (91 missense mutations and five in-frame indels in
43.1% of all 183 cases), which is consistent with activation of the
PI3K-Akt pathway in breast cancers17,18. The majority of the
missense mutations occurred at hotspot positions. The most
frequently mutated amino-acid residue was H1047R/L (65.9% of
91 missense mutations); 12 other missense mutations (6.5%) were
also observed on known PIK3CA hotspots19, suggesting that
PIK3CA mutations are likely activating mutations and functional
drivers of CMTs (Fig. 1b). Mutations on other genes in the PI3K-
Akt pathway were also frequently observed: PTEN mutations
(nine missense, two nonsense, and thee frameshift indels; 6.5% of
cases), PIK3R1 mutations (two missense, one splicing and two
frameshift; 6.0% of cases), and AKT1 mutations (eight
missense, all on the known E17K hotspot; 4.9% of cases)20
(Fig. 1b). Overall, 55.7% of the CMTs harbored at least one non-
silent mutation in four PI3K-Akt pathway genes. Of note,
although most of the mutations within the PI3K-Akt pathway
were widespread across different histology types, AKT1
mutations were exclusively observed in complex carcinomas
(0/78 vs 8/44 in simple and complex carcinomas, respectively;
P= 0.0002, Fisher’s exact test), suggesting a tissue-specific role of
the mutation.
Recurrent mutations in CMT outside the PI3K-Akt pathway
showed intertumoral heterogeneity. KRAS mutations were found
in 19 cases (10.4%), a relatively higher rate than that in human
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breast cancers (5%)21. All observed SNVs in KRAS were located
on three known hotspots: 14 p.G12D/V/A substitutions, p.G13C,
and p.E63K, with no silent mutations. This indicates KRAS
mutation as another major driver of CMT. Truncating mutations
in NF1 (one frameshift indel and two splicing mutations with two
missense mutations) and in SF3B1 (one splicing mutation) were
also observed in CMT, findings that are consistent with
truncating mutations in human breast cancers (1.5% of putative
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P = 7.95e – 154 (U-test)
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Fig. 1 Landscape of somatic mutations in CMT. a The mutational landscape of 183 CMTs (40 benign and 143 malignant CMTs) are shown for nine
recurrently mutated genes. For benign and malignant CMTs, major histology types are shown at the top. Six mutation classes with respect to functional
changes in the encoded amino acids are shown according to the color legend. b Non-silent mutations in four PI3K-Akt pathway genes are shown in lollipop
plots. c Mutant allele frequencies of 3968 and 497 mutations in benign and malignant CMTs are compared. d dNdScv values are compared between 38
benign and 136 malignant CMTs. The significance was estimated by two-sided U tests. For all boxplots in this manuscript, the median and 1st/3rd quartiles
of the data were plotted as the center line and the lower/upper boundaries. Whiskers represents the minimum and maximum of the data after removing
outliers, which were defined as values smaller than 1st quartile – 1.5× IQR (interquartile range) or larger than 3rd quartile+ 1.5× IQR.
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driver mutations and mutations of unknown significance in NF1
and SF3B1, respectively)21.
We further found that novel recurrent mutations at hotspot
sites may account for species-specific mechanisms of carcinogen-
esis and progression in CMT. Encoding Ki-67 protein, a
proliferation marker, MKI67 was frequently mutated in our
cohort (6.0% cases; six missense mutations and two in-frame
indels). Although Ki-67 protein levels have been proposed as a
proliferation marker for discriminating luminal A and luminal B
subtypes, no recurrent MKI67 mutations have been reported in
human breast cancers. The recurrent nature of MKI67 mutations
in CMT, as well as the presence of mutation hotspots (e.g., six
non-silent mutations occurred at a single amino-acid residue of p.
C1606), is indicative of a potential oncogenic role for MKI67
mutations in CMTs.
Germline predisposing variants in CMT. To identify predis-
posing genetic events in CMT genomes, we detected 2005
germline variants (1124 SNVs and 881 indels) that are uncom-
mon (novel or minor allele frequency <5%) and potentially
damaging (i.e., truncating, likely pathogenic or pathogenic)
(Supplementary Data 5). First, we found 10 cases harboring
germline predisposing variants in BRCA1/2 genes, the prevalence
of which (5.5%, 10/183) is slightly higher than those of human
cancers (2.9–3.0%), measured in a meta-analysis of unselected
breast cancer patients22. Among six BRCA1/BRCA2 mutations
observed, four (two BRCA1 and two BRCA2 mutations) were
stop-gain or nonsense mutations indicative of the potential
functionality. Of interests, five out of the 10 BRCA1/2 germline
variants harboring cases were observed in complex carcinomas
suggestive of tissue type-specific mutations along with AKT1
somatic mutations (Supplementary Fig. 1). High prevalence of
BRCA1/2 germline has been reported in basal-like and triple-
negative breast cancer (TNBC) in human (14–15%)22, suggesting
that the impact of inherited deficiency of BRCA1/2 is not uni-
versal, but context-specific in both species.
Mutation enrichment analysis on nine DNA damage-repair
pathways23 further identified that genes harboring germline
variants are significantly enriched in homology-dependent
recombination (HDR) pathway (P= 0.029; Fisher’s exact test,
see Table 1). Other than BRCA1/2, 10 additional mutations were
observed in the genes involved in HDR pathway (NBN, NSMCE1,
POLD1, RECQL4, RMI1, RTEL1, SLX4, SMC5, TOP3B, and
XRCC3), which may be also responsible for the CMT pathogen-
esis as shown in the example of NBN germline variants and
associates breast cancer risk24.
Global patterns of somatic mutations. Analyzing tumor muta-
tion burden (TMB) (i.e., number of exonic mutations in a given
genome), we recorded 10–198 exonic mutations per case of CMT
(median of 30 and mean of 43.5 exonic mutations per case),
except for an outlier with 2939 mutations. Compared with CMT,
human breast cancers21 showed significantly higher level of TMB
overall, i.e., n= 981 cases in the TCGA consortium; 45 median
and 92.8 mean exonic mutations per case (P= 1.9e-9, U test;
Supplementary Fig. 2).
The mutation spectra and the functional consequences of
mutations (e.g., changes in coding residues) were overall constant
among CMTs (Supplementary Fig. 3). Considering the outlier
case (CMT-033; 2939 exonic mutations) as hypermutated, the
frequency of hypermutation in CMT (0.54%; 1 out of 183) was
lower than that in human breast cancer (2.03%, 20 out of 981;
cutoff for hypermutation >10 mutations per Mb). Although no
mutations were observed in proofreading DNA polymerases
(POLD1 and POLE) in CMT-033, we observed one truncating
somatic mutation in MUTYH and missense mutations in genes
encoding DNA damage-repair pathways, such as LIG1, LIG3,
XRCC5, BRCA2, and XPC (Supplementary Data 4), which may
contribute to a mutator phenotype for the CMT genome. In
addition, 43 germline predisposing variants were observed in
CMT-033 but no variants were found in DNA damage-repair
pathways (Supplementary Data 5).
Next, we examined the base substitution patterns of the somatic
mutations based on the frequencies of 96 trinucleotides. We found
that the trinucleotide frequencies were mostly similar across the
examined CMT cases (Supplementary Fig. 4a). We first employed
de novo mutation signature deconvolution based on non-negative
matrix factorization (NMF) and Wellcome Trust Sanger Institute
(WTSI) mutation signature framework (https://kr.mathworks.com/
matlabcentral/fileexchange/38724-sigprofiler)25,26. Both methods
revealed mutation signatures similar to Signature #1 (Sanger ver.
2 30 COSMIC mutation signatures #1 to #30, cosine similarity of
0.74–0.86) (Supplementary Fig. 4b, c) suggesting Signature #1
represents a major mutation signature in CMT genomes. We
further employed mutation signature assignment analyses to
estimate the levels of 30 COSMIC mutation signatures for all
CMT genomes. Consistently, we observed that a single mutation
signature of Signature #1, which represents age-related mutations,
were prevalent in all CMT genome profiles (Supplementary
Fig. 4d). These findings indicate that the mutation forces active
during the carcinogenesis of CMT are largely uniform across
individual cases and highlight spontaneous deamination leading to
C-to-T transitions at CpG dinucleotides as the major contributor
of somatic mutations therein (Supplementary Fig. 4c).
Mutations in early cancer development and progression.
Inclusion of multi-type benign tumors in the cohort (43 out of
191, 22.5%) allowed us to directly compare genomic mutation
profiles between benign and malignant tumors, which has rarely
been undertaken in human cancer studies. As shown in the
Table 1 Germline variants of CMT in DNA damage-repair pathways.
Function Genes P value Genes with predisposing germline variants
Homology-dependent recombination (HDR) 88 0.029 BRCA1, BRCA2, NBN, NSMCE1, POLD1, RECQL4, RMI1, RTEL1, SLX4, SMC5, TOP3B, XRCC3
Fanconi anemia (FA) 41 0.081 BRCA1, BRCA2, FAN1, RMI1, SLX4, TOP3B
Direct repair (DR) 4 0.266 MGMT
Non-homologous end joining (NHEJ) 23 0.519 NBN, RIF1
Mismatch repair (MMR) 24 0.542 PMS1, POLD1
Base excision repair (BER) 47 0.689 APEX1, NEIL3, POLD1
Translesion synthesis (TLS) 20 0.787 POLI
Nucleotide excision repair (NER) 51 0.901 ERCC6, POLD1
Nucleotide pools (NP) 5 1.0 −
The level of significance (P value) was estimated with Fisher’s exact test.
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mutation profiles (Fig. 1a), PIK3CA mutations were frequently
found in the benign tumors, suggesting that this key driver
mutation is commonly acquired in advance of malignant pro-
gression. In contrast, TP53 mutations were found only in
malignant CMTs (0 out of 43 benign vs 16 out of 148 malignant
CMTs; P= 0.025, Fisher’s exact test). This suggests that TP53
mutations may arise as late evolutionary events in malignant
progression, instead of CMT-initiating drivers. Likewise, KRAS
mutations were over-represented in malignant tumors, particu-
larly in complex carcinoma, being indicative of late events in the
transformation to mesenchymal phenotypes27.
We further examined and compared mutation abundance and
composition between the benign and malignant tumors. The
TMBs of the benign and malignant tumors were similar (P=
0.60, U test; Supplementary Fig. 2). Given the tumor purity has
been proposed as a confounding factor in evaluating TMB, we
further adjusted TMB with respect to the estimated tumor
purity28. Consistently, no statistically significant difference was
observed between the purity-adjusted TMB of benign and
malignant CMTs (P= 0.44, U test). These findings suggest that
the abundance of mutations largely remain the same during
malignant progression. However, two mutation-based measures
associated with tumor evolution (mutant allele frequencies
(MAFs) and sample-wise dNdScv scores29 (dN/dS ratio))
provided clues on potential transforming events during benign-
to-malignant progression. We found that the MAFs of malignant
CMTs were significantly higher than those of benign CMTs (P=
7.95e-154; U test) (Fig. 1c), indicating that the malignant
progression of CMT may accompany clonal selection events
affecting subclonal mutation architecture, such as clonal sweeps.
In addition, sample-wise dNdScv scores reflective of degrees of
positive selection on individual cases29 were also substantially
higher in malignant CMTs than in benign CMTs (mean dNdScv
score of benign and malignant CMTs being 0.73 and 0.91,
respectively) although not significantly different (P= 0.069; U
test) (Fig. 1d). This demonstrated that the mutation composition
of malignant CMTs shifts towards non-synonymous mutations,
making them more likely to endure positive selection, compared
with benign CMTs29. Gene-wise application of dNdScv scores
revealed that the top 14 genes with positive selection (false
discovery rate or FDR < 0.3; Supplementary Table 1) included
four genes in the PI3K-Akt pathway (PIK3CA, PIK3R1, PTEN,
and AKT1) and frequently mutated genes, such as KRAS and
TP53. In particular, no silent or synonymous mutations were
observed in the four PI3K-Akt pathway genes. Taken together,
the molecular mechanisms underlying the progression of CMT
can be modeled as (i) the emergence of early oncogenic mutations
(e.g., PIK3CA mutation) in benign tumors, (ii) subsequent
acquisition of additional drivers accompanying malignant
transformation (e.g., TP53 and KRAS mutations), and (iii) clonal
domination of malignant subclones with genomic footprints (e.g.,
MAF and dN/dS ratios).
Somatic copy number aberrations in CMT. Somatic copy
number alterations (SCNAs) were profiled according to the read
depth ratios of tumor and matched normal sequencing data.
Genome-wide profiles of chromosomal copy number gains and
losses in CMT are depicted across histologic types in Fig. 2a
(shown in the order of the cases in Fig. 1a). Among the histologic
types, SCNA-frequent cases were enriched in simple carcinoma,
which is consistent with a previous report16. Genomic fractions
with copy number imbalances were significantly higher in
malignant CMTs than in benign CMTs (P= 0.0011; U test,
Fig. 2b), suggesting that the genomic instability leading to SCNA
is a late evolutionary event occurring after malignant progression.
We also observed that genomes harboring TP53 mutations more
commonly had SCNAs than genomes that did not (P= 8.8e-06;
U test, Fig. 2b), supporting the notion that TP53 mutations lead
to the accumulation of genomic instability and aneuploidy in
cancer genomes16.
In regards to specific genes, recurrent SCNAs were observed on
AKT1 (amplified in 2.7%) and PTEN (deleted in 10.9%).
Approximately two-thirds of the cases (113 CMTs, 61.7% of the
cohort) showed genomic aberrations in PI3K-Akt pathway genes,
harboring either somatic mutations or SCNAs in PIK3CA, PTEN,
PIK3R1, and AKT1. We further performed GISTIC analysis to
identify 18 recurrent amplification and 49 recurrent deletion
peaks across the CMT genomes (Supplementary Table 2). The
identified GISTIC peak regions mirrored known cancer-related
genes (i.e., Cancer Gene Census30) (Fig. 2c). Among the
recurrently amplified and deleted loci, we noted that canonical
oncogenes, such as EGFR and HRAS, were recurrently amplified
in CMTs; however, amplification of ERBB2 and MYC, which is
common in human breast cancers, was not reflected in the
GISTIC peaks of CMTs. Thus, we further examined the genomic
amplification patterns of EGFR in comparison to those of ERBB2
and MYC (Supplementary Fig. 5). In the case of EGFR, minimal
amplification patterns around the genetic locus were observed
and exhibited typical alteration patterns of functional oncogenes
(Supplementary Fig. 5A). However, ERBB2 amplification was
often observed as arm-level events or separate from pter-located
GISTIC peaks, including ASPSCR1 and RNF213 (Supplementary
Fig. 5B), which is in stark contrast to the minimal amplification of
ERBB2 observed in human breast cancers (Supplementary Fig. 5B,
inlet). Together with the low concordance between the copy
numbers and gene expression levels of ERBB2 in CMT (r= 0.09,
measured in this cohort), unlike in human breast cancers (r=
0.857), we can assume a reduced role and limited clinical value for
ERBB2 in CMT, as was previously proposed9,10. Similarly, MYC
amplification was frequently present at the chromosomal level,
which resulted in an inability to detect MYC by GISTIC peaks
(Supplementary Fig. 5C). Also, low correlation between copy
numbers and gene expression levels (r= 0.093) was observed for
MYC in CMT, in contrast to human breast cancers (r= 0.247).
Regarding other genes, recurrent TERT amplification was noted;
the prognostic implications thereof have been described for
human breast cancers31. We also observed recurrent loss of genes
with roles in genomic instability, including ATM and TP53,
which are well-recognized cancer-associated genes in human
cancers.
Transcriptome analysis of CMT. RNA-seq data were available
for 157 tumors and 64 matched normal CMTs. We first applied
NMF for the CMT transcriptome data set to delineate key tran-
scriptional features or metagene signatures at the bulk level.
Cophenetic scores showed that at least five metagene signatures
were present in the transcriptome data set (Supplementary Fig. 6).
Among the five metagene signatures (annotated NMF1–NMF5),
three were relatively specific to CMTs (NMF1, NMF2, and
NMF3); the other two signatures (NMF4 and NMF5) were spe-
cific to adjacent normal breast tissues (black and gray, respec-
tively; Fig. 3a). We further performed gene set enrichment
analysis to identify molecular functions associated with the five
metagene signatures (Supplementary Table 3). According to the
enriched molecular terms (based on the Hallmark gene set of
MSigDB), we could annotate three tumor-specific metagene sig-
natures as “mitosis” (NMF1), “DNA repair” (NMF2), and “epi-
thelial-to-mesenchymal transition” (EMT) (NMF3). Likewise, the
other two normal tissue-specific signatures were annotated as
“estrogen-late” (NMF4) and “estrogen-early” (NMF5). The
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Fig. 2 Somatic copy number alterations (SCNAs) in CMT genome profiles. a A genome-wide heatmap of SCNAs is depicted, with red and blue
representing chromosomal gains and losses, respectively. The cases are listed in order as in Fig. 1a. b Genome fractions with SCNAs were compared
between 40 benign and 143 malignant CMTs, as well as between CMTs with or without TP53 mutations (n= 16 and 167, respectively). c Amplification and
deletion peaks identified by GISTIC algorithms are shown across canine genomes with cancer-related genes belonging to the peaks shown. The significance
was estimated by two-sided U tests.
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enrichment plots and top-enriched genes (i.e., leading edge genes)
for the selected functions of the five metagene signatures are
shown in Supplementary Fig. 6. Marker gene expression analysis
revealed that NMF3 CMTs showed upregulation of the EMT
markers SNAI1/2, ZEB1/2, and TGFB1. Of note, NMF3 CMTs
further showed down-regulation of claudin-encoding genes
(CLDN3, CLDN4, and CLDN7), as well as E-cadherin (CDH1).
Along with a high degree of correlation between gene expression
in NMF3 CMTs and that in tumor-initiating cells (“Signature
correlation” in Fig. 3a), these findings suggest that NMF3 CMTs
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We further assessed whether the metagene signatures held any
prognostic significance. Re-classification of the 157 CMT tumors
with the five metagene signatures assigned 145 tumors to one of
the three tumor signatures (97, 35, and 18 to NMF1, NMF2, and
NMF3, respectively), which were subjected to survival analysis.
Log-rank tests revealed significant differences in overall survival
across the three CMT clusters (P= 0.010, log-rank test;
Kaplan–Meyer survival curves in Fig. 3b), with the least favorable
prognosis for the NMF3 CMTs with activated EMT. Although
evidence of EMT has been reported in a few canine tumors33,34,
our analysis establishes the presence of an EMT subtype and its
association with poor prognosis in CMT, as in multiple human
cancers35. Interestingly, the NMF3 cluster was enriched with rare
CMT subtypes, including carcinosarcomas and osteosarcomas
(Fig. 3c). As claudin-low subtypes are known to be enriched with
tumor-initiating cells or stem cells that can differentiate into
either myoepithelial or luminal progenitors in the hierarchy of
mammary epithelial development36, the molecular features of
NMF3 CMTs resembling those of claudin-low subtypes may be
responsible for the presence of rare CMT histology subtypes with
mixed epithelial and mesenchymal components, such as carci-
nosarcomas. To further evaluate the clinical relevance of NMF3
CMTs in an extended cohort of human breast cancers, we
obtained four expression profiles in public database (GSE17907,
GSE20711, GSE25066, and GSE31519). Patients with high NMF3
metagene scores showed unfavorable clinical outcomes, i.e.,
significantly different survival was observed for two of four
cohorts (Supplementary Fig. 8). In addition, high EMT scores
were observed for those with high NMF3 metagene scores.
Next, we examined relationships among the metagene
signatures with intrinsic molecular classification (e.g., luminal
A, luminal B, Her2-enriched, and basal-like subtypes) for human
breast cancer37. To apply the intrinsic human breast cancer
subtypes to CMT, we focused on the expression of genes
belonging to PAM50 in the expression profiles of human breast
cancers and CMT. After merging the expression profiles,
hierarchical clustering thereof largely segregated CMT tumors
into two classes, one of which segregated with luminal A (non-
basal CMTs) and the other with basal-like subtypes of human
breast cancers (basal CMT) (Supplementary Fig. 7). We noted
that ERBB2 overexpression was exclusive to Her2-enriched
human breast cancers; it was not observed in other human
breast cancer subtypes and CMTs. Basal CMT showed significant
unfavorable clinical outcome in terms of survival, compared to
non-basal CMTs (P= 0.004, log-rank test). In addition, basal
CMTs were enriched with NMF3 CMTs and rare histological
subtypes of CMT. Altogether, application of human breast cancer
molecular subtyping to CMTs revealed that a subset of CMTs
sharing the clinical behavior and histologic presentation of NMF3
CMTs is transcriptionally similar with basal-like human breast
cancer. However, the results did not support the presence of
Her2-enriched human breast cancer subtypes in our CMT cohort.
The presence of EMT-related NMF signatures and their
associations with CMT suggested that the tumor
microenvironment affects CMT pathogenesis. Accordingly, we
applied the ESTIMATE algorithm38 to estimate the relative
fraction of stromal and immune cells in the CMT microenviron-
ment. The analysis revealed significantly different ESTIMATE
stromal scores among the three NMF classes (P= 5.18e-18,
analysis of variance; ANOVA) (Fig. 3d). Higher stromal scores
for NMF3 CMTs than for NMF1-NMF2 CMTs suggested higher
degrees of stromal cell infiltration in NMF3 tumors. Accordingly,
we deemed that the EMT-representing transcripts in NMF3
tumors may likely be derived from tumor-infiltrating stromal
cells instead of tumor cells, consistent with a recent observation in
mouse xenograft models39. Although no significant differences in
ESTIMATE immune scores were observed among the three NMF
classes (P= 0.388, ANOVA), it is possible that activated EMT
may still impact the immune contexture or the immune cell
composition in CMT, as only total immune cell counts are
reflected in ESTIMATE immune scores. Thus, we further applied
the CIBERSORT algorithm to estimate and compare the relative
abundance of 22 immune cells among the NMF classes40. Twelve
immune cell types showed significant differences (P < 0.05,
ANOVA) among three NMF tumor types, as shown in Fig. 3e.
We noted that NMF3 CMTs were relatively depleted of tumor-
infiltrating immune cells, such as naive B cells, CD8 T cells,
nature killer cells, and monocytes, compared with NMF1 and
NMF2 CMTs. The enrichment of M0 and M2 macrophages was
observed for NMF3 CMTs, suggesting that macrophages are the
major immune component in the microenvironments thereof.
We presume that NMF3 CMTs favor the polarization of M0
macrophages to M2 macrophages, which are important in
inflammation and tissue repair, instead of M1 proinflammatory
macrophages.
Cross-species genomic alterations of canine and human breast
cancers. For cross-species comparison of pathway-level muta-
tions and SCNAs between CMT and human breast cancer, we
examined 13 genes belonging to two signaling pathways (the
PI3K-Akt and p53 pathways), particularly in regards to the fre-
quencies of activation or inactivation thereof in benign and
malignant CMTs and in human breast cancer (Fig. 4a). Four
genes in the PI3K-Akt pathway, PIK3CA (55%, 38%, and 39%
activated in benign CMT, malignant CMT and human breast
cancer, respectively), PTEN (4%, 20%, and 13%), PIK3R1 (2%,
10%, and 8%), and AKT1 (0%, 9%, and 4%), showed comparable
alteration frequencies between benign/malignant CMTs and
human breast cancers, indicating that mutations in the PI3K-Akt
signaling pathway are conserved across species in breast cancer
pathogenesis. In addition, the higher mutation frequencies of
PIK3CA in benign CMTs, compared with malignant CMTs and
human breast cancers, highlight the early oncogenic roles of
PIK3CA mutations. Other genes showed relatively lower altera-
tion frequencies in CMTs than in human breast cancers,
including TP53 (inactivated in 0%, 15%, and 48% of benign
CMTs, malignant CMTs, and human breast cancers, respec-
tively), as well as EGFR, ERBB2, ATM, and CHEK2. In addition,
Fig. 3 Molecular taxonomy and tumor microenvironments of CMT based on transcriptomic analyses. a Five NMF metagene signatures are identified
(NMF1–NMF5) with functional annotations. A heatmap shows that three NMF metagene signatures (NMF1–NMF3) are upregulated to varying degrees in
CMT tumors (black), whereas NMF4 and NMF5 signatures are upregulated in normal tissue transcriptomes (gray). NMF clusters for individual CMTs are
assigned according to the level of five NMF metagene signatures. The expression of selected EMT markers and claudin genes is also shown in a heatmap.
The degrees of correlation between the expression signatures of tumor-initiating cells and CMT transcriptomes are depicted in signature correlation.
b CMT tumors are classified into three subtypes (NMF1, NMF2, and NMF3), and their respective Kaplan–Meier survival curves are shown. The significance
of survival differences across NMF clusters was estimated by log-rank test (two-sided). c Three NMF CMT subtypes were compared with histology types.
d ESTIMATE-derived stromal and immune scores are plotted against the three NMF CMT clusters (92 NMF1, 35 NMF2, and 18 NMF3 CMTs, respectively).
e Relative abundance of 12 immune cell subtypes estimated by CIBERSORT algorithms are shown for 92 NMF1, 35 NMF2, and 18 NMF3 CMTs.
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Fig. 4 Cross-species comparison of mutations and SCNAs. a For two major signaling pathways (PI3K-Atk and p53 pathways), the respective levels of
activation and inactivation (red and blue, respectively) for 13 genes are shown. For each gene, activity levels are shown for benign CMTs, malignant CMTs,
and human breast cancers, respectively. b CMT SCNAs are aligned onto the human reference genome (hg19) and compared with SCNA profiles of human
breast cancers in the linear space of hg19 (chr1 to chr22 with sex chromosomes). The degrees of amplification and deletion are presented as the sum of
log-ratios in hg19-aligned CMT and human breast cancer cohorts. c Chromosome 5 is shown, where human breast cancer shows arm-level 5p gains and 5q
losses. The hg19-aligned CMT genomes show a deletion peak harboring PIK3R1. d Chromosome 8 shows peaks in six genes of hg19-aligned CMT SCNAs
(CSMD, PSD3, IDO1, STK3, MYC, and PTK2), along with FGFR1 in an amplification peak of human breast cancer SCNAs.
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AKT3, MDM2, and MDM4 were rarely altered in CMTs. The
relative lack of alterations in genes other than PI3K-Atk pathway
genes may indicate that a limited repertoire of mutations is suf-
ficient to give rise to CMT in a relatively short time, compared
with human breast cancer development. Nevertheless, additional
studies are required to investigate whether mutations less fre-
quent in CMT genomes, such as ERBB2 amplifications, have
similar biological or clinical implications as those in human
breast cancers or whether they merely represent redundant
alterations arising in the background of neutral mutations. The
non-silent mutation frequencies of CMT genomes are compared
with those of human breast cancers in Supplementary Data 6.
Finally, we transformed the CMT SCNA profiles by synteny
realignment (canFam3.1) onto the human reference genome
(hg19) using the blastz alignment algorithm41 (see Methods).
SCNA profiles of hg19-aligned CMT genomes and human breast
cancers are shown in Fig. 4b. We noted that cross-species
correlations between segment-level amplifications and deletions
were not strong (r= 0.225 and 0.037 for amplifications and
deletions, respectively). However, major peaks in CCND1 (11q
gain), CDKN2A (9p loss), and PTEN (10q loss) were concordant
between dogs and humans. Owing to the different chromosomal
constitutions of the two species, a single large (e.g., arm-level)
SCNA event in human breast cancers may be represented by
multiple SCNA events in CMT, helping to pinpoint regions of
functional relevance. In chromosome 5, we observed a narrow
deletion peak involving PIK3R1 in the hg19-aligned CMT
SCNAs, which has been shown to reflect arm-level losses of 5q
in human breast cancer SCNAs, suggesting functional relevance
in terms of PI3K-Akt signaling (Fig. 4c). Likewise, in chromo-
some 8, arm-level gains of 8q and losses of 8p in human breast
cancer SCNAs were further segmented into three amplification
peaks involving STK3, MYC, and PTK2 and three deletion peaks
involving CSMD1, PSD3, and IDO1 in hg19-aligned CMT
SCNAs, respectively (Fig. 4d). These cross-species comparative
oncogenomic results exemplify how genomic analysis of CMT
can lead to the better understanding of human breast cancers.
Discussion
In this study, we conducted a comprehensive genomic analysis of
CMT at the cohort level. Exome- and transcriptome-sequencing
based molecular characterization revealed somatic mutations and
SCNAs in CMTs at an unprecedented scale. Compared with the
molecular characteristics of human breast cancers21, notable
similarity in terms of core oncogenic signatures including key
genes of the PI3K-Akt and p53 pathways were identified. We
were also able to uncover species-specific molecular character-
istics, such as uncertain role for ERBB2 amplification in CMTs,
and mutations prevalent in benign tumors that may reflect the
early genetic basis underlining the initiation of CMT pathogen-
esis. Finally, gene expression-based molecular taxonomy revealed
the presence of an EMT-associated subtype in CMTs with an
unfavorable prognosis. Overall, our study highlights the mole-
cular convergence of key oncogenic pathways and supports the
potential use of therapeutics for human breast cancer in dogs with
CMTs42.
Domestic dogs have a much shorter life expectancy than
humans (10–13 vs 79 years), and tumorigenesis in dogs is
accomplished within a shorter period (~10 years). The relatively
shorter period for cancer onset may be responsible for the unique
features of CMT. For example, the relative paucity of aneuploidy
and SCNA drivers, such as ERBB2 amplifications in CMT,
compared with human breast cancers, may be attributed to the
shorter development time of the disease, as aneuploidy has often
been considered as a late-stage marker43. Less-abundant mutation
burdens of CMT compared with human breast cancers suggests
that the mutational composition for breast cancer development
may be different across species and those of CMT are relatively
simpler compared with human breast cancers. It will require
further investigation to see whether the additional mutations
acquired by human breast cancer genomes merely represent the
driver-accompanying neutral alterations or confer additional
benefits. In addition, we found that CMT genomes showed
relatively uniform TMB levels and sequence compositions (e.g.,
mutation signatures). This indicated that the mutational settings
giving rise to CMT may be achieved at similar ages.
Of interest, TMB levels were comparable between benign and
malignant CMTs in this study. This has also been demonstrated
for other tumor types, including colorectal cancers44, raising two
possibilities. The first possibility is that an optimal or tolerable
TMB level is fixed for a given cancer cell such that malignant
progression allows for only an essential, but limited, number of
additional mutations to be acquired. This assumption may be
supported by our finding of cross-species similarities in CMT and
human breast cancers in terms of PI3K-Akt pathway aberrations.
The second possibility is that genetic programs favoring benign
and malignant disease are determined early instead of following
traditional stepwise acquisition of mutations during disease
progression. Nevertheless, since the presence of mutations enri-
ched in malignant disease, such as TP53 and KRAS mutations,
supports that the malignant progression of CMT may follow
traditional stepwise evolution, determining whether the malig-
nant progression of CMT proceeds in accordance with traditional
stepwise or parallel evolution will require further investigation
with an extended longitudinal setting (e.g., comparison of mul-
tiple samples from the same individual). In addition, we found
that measures representative of clone- and gene-level selective
forces, such as MAF and dNdScv, indicated that the malignant
progression of CMT involves selection events that alter the fre-
quencies and compositions of somatic mutations. Thus, whether
such selection events are responsible for or are independent of
malignant progression need to be determined.
Our research also raised questions as to whether the intrinsic
mechanisms for suppressing cancer development (e.g., DNA
repair, cell cycle arrest, or immunosurveillance) are intact or not
in CMT. The predominance of a single type of mutation signature
(Signature #1) in the CMT genomes suggested that the majority
of somatic mutations may be those accumulated during the life-
time of a host, with a limited impact of other mutagenic sources
in human breast cancers45 (e.g., APOBEC overactivity and BRCA
deficiency). However, no correlation was observed (r= 0.04)
between host age and the levels of Signature #1 and it is possible
that somatic mutations of CMT genomes have arisen in a limited
time period such as a mutational burst, or at least have accu-
mulated in a non-gradual manner probably associated with a loss
of DNA repair mechanisms. The identification of susceptibility
factors for somatic mutations may also lead to developing means
of reinforcing tumor-suppressing systems in both dogs and
humans.
As the fierce battle with cancer is now expanding to companion
animals, treatment of canine cancer itself is becoming an
important issue. Although anticancer agents originally developed
to treat human cancers may be applied to dogs, little evidence has
been given in terms of their therapeutic efficacy, especially in
relation to cost effectiveness. Recently, a study of drug sensitivity
showed trametinib (a MEK1/2 inhibitor) to be effective in canine
cancer cell lines46, and we expect more lines of evidence will
accumulate on trans-species use of more drugs of these kinds. In
spite of a concern regarding the discordance between animal and
human in drug efficacy and toxicities47, treatment of canine
cancer may benefit from the development of novel human cancer
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drugs that target shared oncogenic mutations (e.g., alpelisib for
metastatic breast cancer with PIK3CA mutations48). We envision
that genomic studies of different cancer types, further stratifica-
tion, and companion diagnostics will lead to more efficient
treatment of canine cancers, just as they have done for human
cancers over last 10 years.
Methods
Detailed information on the study design, sample collection, data generation, and
quality control strategies has been described in a separate data descriptor paper49.
Here, we have provided a brief overview of the data that are essential to under-
standing the presented study: some parts of this section may contain overlapping
descriptions with the data descriptor paper, especially for the conventional
protocols.
Cohort design and sample collection. The cohort was designed as a tumor and
matched normal control cohort to facilitate the investigation and comparison of
genomic and transcriptomic features. In available cases, blood (buffy coat) and
adjacent normal mammary tissues were used as controls for tumor DNA and RNA,
respectively. In total, 191 dogs with mammary tumors were recruited via private
veterinary clinics in Korea, with informed consent from their owners. Tumor
tissues, adjacent normal tissues, and blood were collected from the dogs following
the guidelines of the Institutional Animal Care and Use Committee of Konkuk
University (KU16106 and KU17162) upon availability. Fresh tissue samples were
immediately transferred to RNAlater (Thermo Fisher Scientific, Vilnius, Lithua-
nia), refrigerated overnight at 4 °C, and stored at −80 °C. Genomic DNA was
extracted from tumor tissue and buffy coats using QIAamp DNA mini kits
(Qiagen, Germany). Total RNA was extracted from tumor and adjacent normal
tissues using RNeasy mini kits (Qiagen).
Histopathology. For histological examination, sections (4-μm thick) from
formalin-fixed paraffin-embedded blocks were stained with hematoxylin and eosin
and were diagnosed by two researchers (B.J.S. and J.H.S.). Histological subtyping
was based on the World Health Organization classification50. The diagnosis of
malignancy, which included ambiguous subtypes (e.g., simple adenoma vs simple
carcinoma (grade 1), complex adenoma vs complex carcinoma (grade 1), benign
mixed tumor vs carcinoma in benign mixed tumor (grade 1)) was determined in
accordance with that described by Rasotto et al.51. Histological grade was assessed
according to the Peña system52, exclusively on the neoplastic epithelial component.
In cases of mammary osteosarcoma and mammary fibrosarcoma, histological grade
was assessed according to the grading system for canine osteosarcoma53 and the
grading system for cutaneous and subcutaneous soft tissue sarcoma in dogs54,
respectively. Lymphatic invasion, defined as the presence of tumor cells in peri-
tumoral lymphatic vessels (all cases) and/or regional lymph nodes (only available
cases), was also determined.
WES and RNA-seq. Among 191 samples, 183 cases with tumor DNA and matched
normal DNA were subjected to WES. Two hundred nanograms of fragmented
DNA was prepared to construct libraries with the SureSelect Canine All Exon Kit
(Agilent, Inc., USA) using the manufacturer’s protocol. In brief, qualified genomic
DNA samples were randomly fragmented by Covaris, followed by adapter ligation,
purification, hybridization, and PCR. Captured libraries were then examined on an
Agilent 2100 Bioanalyzer to evaluate quality and were loaded on an Illumina HiSeq
sequencer, according to the manufacturers’ recommendations. In addition, 157
tumor tissues and 64 matched, normal, adjacent tissues with RNA available were
also subjected to RNA-seq. Before library construction, RNA 6000 Nano kits
(Agilent Technologies, CA) were used to assess RNA quality. For cDNA library
construction, 1 μg of RNA was obtained and purified with oligo-dT magnetic
beads. Fragmentation was performed with purified mRNA, and double-stranded
cDNAs were synthesized. The cDNAs were primed with poly-A, and sequencing
adapters were connected using TruSeq RNA sample prep kits (Illumina, CA).
Fragments were filtered to a specific length using BluePippin 2% agarose gel cas-
settes (Sage Science, MA), and PCR amplification was conducted. Fragment lengths
and quality were electrophoretically verified with Agilent High Sensitivity DNA kits
(Agilent Technologies, CA). Libraries were observed with a window spanning an
average of 392 bp, standard deviation of 66 bp. WES and RNA-seq were performed
using Illumina HiSeq 2500 (Illumina, CA) with the protocol out-sourced to
Theragenetex Inc.
Processing of sequencing data. WES reads were aligned to the CanFam3.1 (Canis
lupus familiaris) reference genome with BWA-MEM255. Duplicate fragments were
marked and eliminated with Picard (version 2.2) (http://picard.sourceforge.net).
After assessing mapping quality and filtering out low-quality mapped reads, paired
read information was evaluated to ensure that all mate-pair information was in
sync between each read. Then, processes of removing PCR duplicates, indel rea-
lignment, fixing mate information, base quality score recalibration, and variant
quality score recalibration on putative SNVs and indels were performed using
GATK4.0 following GATK Best Practices recommendations56 with CanFam3.1
(Ensembl Release 91) as a reference. The whole pipeline was implemented in-
house49. RNA-Seq data of the 157 tumor samples and 64 normal, adjacent samples
were mapped to the canine reference genome CanFam3.1 using splice-aware
aligner of TopHat57 (v.2.0.9), with Ensembl gene annotation and fr-firststrand
library type. FPKM (fragments per kilobase of transcript per million) values were
calculated by Cufflinks58 (v2.1.1) using aligned bam files.
Germline variants calling and annotation. GATK-HC59 (v4.1.5.0) was used to
call germline variants in paired bulk data and filtered by VariantFiltration of
GATK4 with the criteria recommended for germline variants; excluding candidates
with QD < 2.0, FS > 60.6, MQ < 40.0, ReadPosRankSum <−8.0, MQRanksum <2.5
or MQRankSum >2.5. Variants with ≥10 depth in both or only in normal sample
were used for further analysis. Variants were liftovered from CanFam3.1 to hg38
with Crossmap60 (v0.2.9) using UCSC chain file (camFam3ToHg38.over.chain.gz).
Variants successfully liftovered to hg38 were annotated using SnpEff61 (v4.3t) and
ClinVar62 (build 2020-03-10). We only kept variants that are tagged as truncated
(stop gained, splice variant, frameshift), pathogenic, or likely pathogenic. Only
novel or uncommon candidates with MAF < 0.05 in Dog Genome SNP Database
(DogSD) (release 2017-06-10)63 from iDOG and within the cohort were included
in the final germline variant list.
Somatic variant calling, filtration, and annotation. We detected single-
nucleotide variations (SNVs) and small insertions/deletions (indels) using
Mutect264 from GATK4 v4.0.10.1. The VCF file produced by the pipeline utilizes
reference bases on the positive strand of CanFam3.1 in the REF field, and variants
are shown in the ALT field. We filtered out falsely detected variants using Filter-
MutectCalls from GATK4 and selected PASS variants from the VCF files. Variant
Effect Predictor was used to annotate identified variants65. To estimate dNdScv
scores, we used R packages (https://github.com/im3sanger/dndscv)29.
We examined the possibility of the somatic mutations being falsely detected by
alignment errors. In the absence of utility for alignment error assessment in canine
genome, we built our in-house workflow to strictly rule out variant sites with
dubious alignment patterns using the aligner-generated alignment scores at
optimal and suboptimal mappings. For each SNV position, passing sequence reads
with an alternative allele were collected to calculate the alignment score at optimal
site (AS), and the alignment score at suboptimal (or secondary) site (XS), which are
averaged over all samples to derive the mean alignment scores at optimal site
(meanAS) and suboptimal site (meanXS). We judged that the candidate SNVs are
likely from alignment errors if the meanXS is greater than or equal to the 80% of
the meanAS (meanXS ≥ 0.8×meanAS).
Tumor purity estimation and TMB adjustment. Tumor purity of CMT genomes
were visually estimated by histological examination of H&E stained slides by a
pathologist (B-J Seung). Only samples with >70% of the judged proportion of
neoplastic cells were used for analysis. In the case of human breast cancers of
TCGA consortium, we obtained consensus purity estimates from a literature66. The
TMB of individual genomes were multiplied with the correction factor corre-
sponding to the purity of the given case, to derive the purity-corrected TMB28.
Copy number variant calling. We calculated the depth of coverage using GATK
and then followed the typical XHMM workflow. SAMTOOLS67 v1.9 and VARS-
CAN68 v.2.4.3 were used to identify SCNAs following the recommended workflow.
First, we ran the mpileup function in SAMTOOLS to estimate the bin-level
sequencing read depth both for tumor and normal BAM files. The ratios of tumor/
normal sequencing read depth were then calculated, and the normalized read depth
ratios were further GC-corrected. We applied the circular binary segmentation
(CBS)69 algorithm for segmentation and used the IGV browser for visualization of
SCNAs70. We also used GISTIC2 to identify recurrent chromosomal gains and
losses of CMT genomes71. For cross-species comparison of SCNAs between CMTs
and human breast cancer, we used the cross-species alignment information of
canFam3 and hg19 assemblies generated by the blastz algorithm (http://
hgdownload.cse.ucsc.edu/goldenpath/hg19/vsCanFam3/). The segment-level log2
ratios of CMT genomes (canFam3.1) were aligned onto hg19 using the blastz
chained alignment. The hg19-aligned SCNA profiles were further smoothed and
segmented using the CBS algorithm.
Transcriptome-based CMT subtypes. We performed NMF deconvolution to
identify latent features in CMT expression profiles by decomposing the log-
transformed CMT expression matrix into a basis matrix (hereafter, NMF metagene
signatures) and metagene expression profiles72. For deconvolution, CMT expres-
sion profiles along with those of normal, adjacent mammary tissues were subjected
to NMF. To determine the optimal number of NMF metagene signatures, we
measured the cophenetic score for 2–10 NMF metagene signatures as a stability
measure. Five NMF metagene signatures were derived including three signatures
representing CMT tumors. We further performed pre-ranked version of gene set
enrichment analysis with functional gene sets (MSigDB, Hallmark category) for
functional annotation of metagene signatures73. For prognostic evaluation of NMF
clusters, Kaplan–Meier survival curves were drawn and log-rank tests were applied
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for three tumor-specific NMF clusters. We also performed molecular classification
of CMT transcriptomes using PAM50 genes. The expression levels of PAM50 genes
for TCGA human breast cancer and CMT tumors were merged and subjected to
hierarchical clustering. To estimate correlations between individual CMT tran-
scriptomes and the expression of tumor-initiating cells, we analyzed 154 up- and
339 downregulated genes of CD44+/CD24− tumor-initiating cells, with signature
correlation levels calculated as previously described32.
Validation of CMT subtypes in human cohort. Four expression profiles of
human breast cancers in public database (GSE17907, GSE20711, GSE25066, and
GSE31519) were obtained with clinical outcomes. Patients in the individual cohorts
were discriminated into high and low NMF3 with the median of NMF3 scores (i.e.,
average expression level of genes in NMF3 metagenes). Patient survival of high and
low NMF3 was compared using log-rank tests and also for the EMT scores as
average expression of genes in EMT/Hallmark MSigDB gene set.
Tumor microenvironment profiling. We used the ESTIMATE R package to
estimate scores representative of the relative proportion of immune and stromal
cells in the admixture of CMT transcriptome data38. To infer the relative abun-
dance of tumor-infiltrating immune cells, CIBERSORT was used, with the
LM22 set representing 22 immune cell subtypes40.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Raw DNA- and RNA-sequencing data are publicly available in Sequence Read Archive
(SRA) with the accession numbers 159481 (DNA-seq) and 159466 (RNA-seq). Gene
expression values are available in Gene Expression Omnibus (GEO) with the accession
number GSE119810. The lists of germline and somatic mutations are available in
Supplementary Data 4 and 5. Single-nucleotide variants and their allele frequencies are
available at the Dog Genome SNP Database (DogSD) from the iDOG website (http://
bigd.big.ac.cn/idog/).
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